Pneumococcal Vaccine Development
Universal pneumococcal vaccination of Italian infants is cost effective
Published in Vaccine Weekly, September 21st, 2005
"This study aimed at estimating the health and economic outcomes of universal infant vaccination with seven-valent pneumococcal conjugate vaccine (PCV-7) in Italy. A Markov model simulated lifetime evolution of a birth cohort (538,138 children): universal vaccination would avert 769 invasive infections, 18 deaths, and 1,323 life years," scientists writing in the journal Vaccine report.
"At base-case analysis, universal three-dose vaccination would cost euro 26,449 (95% CI: 1975-62,075) and euro 38,286 (95% CI: 22,164-70,801) per life year-saved in the societal and the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2005-09-21)
More Articles from Vaccine Weekly
- Cancer Vaccine Development
Dendritic cell vaccine accelerates CD8+ memory and prime-boost response - Cancer Vaccine Development
Human carcinoembryonic antigen-based cancer vaccines reviewed - Cancer Vaccine Development
Mimotope peptide-based anti-cancer vaccine developed - HIV/AIDS Vaccine
HIV type 1 Tat protein induces neutralizing antibodies - Helicobacter Vaccine Development
Vaccine development for gastric cancer and Helicobacter reviewed - Addiction Medicine
Vaccine pharmacotherapy for treatment of cocaine dependence determined - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
